AML through the prism of molecular genetics
- 1 January 2020
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 188 (1), 49-62
- https://doi.org/10.1111/bjh.16356
Abstract
Modern management of acute myeloid leukaemia (AML) relies on the integration of phenotypic and genetic data to assign classification, establish prognosis, enhance monitoring and guide treatment. The prism through which we can now disperse a patient's leukaemia, interpret and apply our understanding has fundamentally changed since the completion of the first whole-genome sequencing (WGS) of an AML patient in 2008 and where possible, many clinicians would now prefer to delay treatment decisions until the karyotype and genetic status of a new patient is known. The success of global sequencing initiatives such as The Cancer Genome Atlas (TCGA) have brought us significantly closer to cataloguing the full spectrum of coding mutations involved in human malignancy. Indeed, genetic capability has raced ahead of our capacity to apply much of this knowledge into clinical practice and we are in the peculiar position of having routine access to genetic information on an individual patient's leukaemia that cannot be reliably interpreted or utilised. This is a measure of how rapid the progress has been, and this rate of change is likely to continue into the foreseeable future as research intensifies on the non-coding genome and the epigenome, as we scrutinise disease at a single cell level, and as initiatives like Beat AML and the Harmony Alliance progress. In this review, we will examine how interrogation of the coding genome is revolutionising our understanding of AML and improving our ability to underscore differences between paediatric and adult onset, sporadic and inherited forms of disease. We will look at how this knowledge is informing improvements in outcome prediction and the development of novel treatments, bringing us a step closer to personalised therapy for myeloid malignancy.Keywords
Funding Information
- Queen Mary University of London
- HCA International Foundation
- Cancer Research UK (C15966/A24375)
This publication has 91 references indexed in Scilit:
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid LeukemiaThe New England Journal of Medicine, 2013
- Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencingNature, 2012
- Relapse of leukemia with loss of mismatched HLA resulting from uniparental disomy after haploidentical hematopoietic stem cell transplantationBlood, 2010
- Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation.The New England Journal of Medicine, 2009
- Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibilityBlood, 2009
- Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcomeBlood, 2009
- DNA sequencing of a cytogenetically normal acute myeloid leukaemia genomeNature, 2008
- Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samplesLeukemia, 2006
- Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemiaLeukemia, 2005
- Familial Leukaemia: A Study of 909 FamiliesScandinavian Journal of Haematology, 1975